{"schema_version":"secwatch.filing_event.v1","accession":"0001639691-23-000010","form_type":"8-K","ticker":"LIVN","cik":"0001639691","company_name":"LivaNova PLC","filed_at":"2023-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.957275+00:00","generated_at":"2026-06-19T04:58:39.133560+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"LivaNova Q4 revenue up 6.2% constant currency; adjusted EPS $0.81","bullets":["Q4 revenue $274.9M (+6.2% constant currency); GAAP EPS $0.03, adjusted EPS $0.81.","FY2022 revenue $1.02B (+2.9% constant currency); GAAP loss per share $1.61, adjusted EPS $2.39.","First clinical cases of Essenz perfusion system completed; LifeSPARC ECMO 510(k) cleared.","FDA Warning Letter for Munich facility and 3T Heater-Cooler closed out."],"urls":{"canonical":"https://secwatch.observer/filing/0001639691-23-000010","json":"https://secwatch.observer/filing/0001639691-23-000010.json","markdown":"https://secwatch.observer/filing/0001639691-23-000010.md","text":"https://secwatch.observer/filing/0001639691-23-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1639691/000163969123000010/0001639691-23-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1639691/000163969123000010/livn-20230215.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T04:58:39.133560+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1c4787635bb8c8978224620ef97945e73268d1c2","claim":"LivaNova PLC updated its FY2023 guidance (initiated).","evidence_excerpt":"LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full year ended December 31, 2022 and issued guidance for 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1639691/000163969123000010/0001639691-23-000010-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"FY2023"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"6b430dd94cd561749320360cb2dd666e75253125","claim":"LivaNova PLC reported Q4 2022 results: revenue $274.9 million, EPS $0.03.","evidence_excerpt":"Fourth-quarter revenue of $274.9 million increased 1.8 percent on a reported basis and 6.2 percent on a constant-currency basis, as compared to the prior-year period • Fourth-quarter U.S. GAAP diluted earnings per share was $0.03 and adjusted diluted earnings per share was $0.81","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1639691/000163969123000010/0001639691-23-000010-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Q4 2022"},{"label":"Revenue","value":"$274.9 million"},{"label":"EPS","value":"$0.03"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"6e3fa838d42b32d1a0b976963ceee52ab1c9f900","claim":"LivaNova PLC reported FY2022 results: revenue $1.02 billion, EPS $1.61.","evidence_excerpt":"Full-year 2022 revenue of $1.02 billion decreased 1.3 percent on a reported basis and increased 2.9 percent on a constant-currency basis, as compared to the prior year • Full-year 2022 revenue, excluding revenue from the Heart Valve business which was divested effective June 1, 2021, increased 2.3 percent on a reported basis and 6.7 percent on a constant-currency basis, as compared to the prior year • Full-year 2022 U.S. GAAP diluted loss per share was $1.61 and adjusted diluted earnings per share was $2.39","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1639691/000163969123000010/0001639691-23-000010-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"FY2022"},{"label":"Revenue","value":"$1.02 billion"},{"label":"EPS","value":"$1.61"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}